Prilenia Therapeutics

Company Overview

Snapshot

Founded in May 2018, Prilenia Therapeutics operates with 51–200 employees. The company has raised a total of $144.5M across 4 funding rounds from 9 investors. In April 2022, SV Health Investors.

Business overview

Prilenia Therapeutics is a late clinical-stage biotechnology company focused on developing novel therapeutics for neurodegenerative diseases and neurodevelopmental disorders. The company's core product is pridopidine, a first-in-class, oral, highly selective, and potent investigational S1R agonist. Prilenia is currently advancing pridopidine through pre-registration for Huntington's disease (HD) and Phase 3 development for amyotrophic lateral sclerosis (ALS), serving the pharmaceutical and biotechnology sectors.

Strategic signal

In March 2024, Prilenia announced its intention to seek European approval for pridopidine for Huntington's disease. This move signals the company's strategic focus on regulatory milestones and market expansion for its lead compound, indicating potential near-term commercialization efforts and validating its clinical development pathway for neurodegenerative treatments.

Company Intelligence Q&A

What is Prilenia Therapeutics' primary focus?

Prilenia Therapeutics is focused on developing novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders, with an initial focus on Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).

What is pridopidine and its current development status?

Pridopidine is Prilenia's lead compound, a first-in-class, oral, highly selective, and potent investigational S1R agonist. It is in pre-registration for Huntington's disease and Phase 3-stage development for amyotrophic lateral sclerosis (ALS).

When did Prilenia Therapeutics enroll its first patients for the PROOF-HD Phase 3 clinical trial in the United States?

In October 2020, Prilenia Therapeutics enrolled its first patients into its PROOF-HD Phase 3 Clinical Trial for Huntington's Disease in the United States.

Which investors participated in Prilenia Therapeutics' Series B funding round in April 2022?

In April 2022, SV Health Investors.

What regulatory designations has pridopidine received?

Pridopidine has received Orphan Drug designation for Huntington's disease and ALS in the U.S. and EU, and Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Huntington's disease.